Key Points
- Insider sale: Harpreet Dhaliwal sold 9,743 Vaxcyte shares on Dec. 31 at an average price of $46.69 for $454,900.67, reducing his stake by 28.94% to 23,928 shares, as disclosed in an SEC Form 4.
- Financials and stock context: Vaxcyte reported quarterly EPS of -$1.56 (missing the -$1.27 consensus) and analysts forecast -4.21 EPS for the year; the stock trades near $46 with a market cap of about $6.08 billion and a 52-week range of $27.66–$93.77.
- Analyst sentiment: Coverage averages a Moderate Buy with an average price target of $97.83, though ratings vary (1 Strong Buy, 7 Buy, 1 Hold, 1 Sell) and price targets range widely among firms.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) insider Harpreet Dhaliwal sold 9,743 shares of the stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the sale, the insider directly owned 23,928 shares in the company, valued at approximately $1,117,198.32. This trade represents a 28.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Vaxcyte Stock Up 0.7%
Vaxcyte stock opened at $46.46 on Friday. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $93.77. The firm has a market capitalization of $6.08 billion, a price-to-earnings ratio of -9.60 and a beta of 1.28. The firm has a 50-day moving average price of $45.88 and a two-hundred day moving average price of $38.67.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.29). During the same quarter in the prior year, the company earned ($0.83) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Hedge Funds Weigh In On Vaxcyte
Institutional investors and hedge funds have recently bought and sold shares of the business. AlphaQuest LLC purchased a new stake in shares of Vaxcyte in the first quarter worth approximately $33,000. Allworth Financial LP increased its stake in Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company's stock valued at $44,000 after buying an additional 731 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in Vaxcyte in the 3rd quarter worth approximately $45,000. CIBC Private Wealth Group LLC boosted its stake in shares of Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company's stock valued at $49,000 after buying an additional 1,350 shares during the period. Finally, CWM LLC grew its holdings in shares of Vaxcyte by 197.3% during the 2nd quarter. CWM LLC now owns 1,680 shares of the company's stock valued at $55,000 after acquiring an additional 1,115 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the stock an "outperform" rating in a research note on Wednesday, November 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vaxcyte in a research report on Tuesday, October 14th. BTIG Research reissued a "buy" rating and issued a $85.00 price target on shares of Vaxcyte in a research note on Monday, November 10th. Finally, The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, September 12th. They set a "neutral" rating and a $38.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Vaxcyte currently has an average rating of "Moderate Buy" and an average price target of $97.83.
View Our Latest Stock Report on Vaxcyte
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
